Preoperative neoadjuvant therapy of mitotane combined with immune checkpoint inhibitors for adrenal cortical carcinoma: a case report

VernacularTitle:米托坦联合免疫检查点抑制剂术前新辅助治疗肾上腺皮质癌1例报告
Author: Guanwen DING ¹ ; Jiang LIU ; Zhan WANG ; Yi LU ; Yu XIAO ; Yang ZHAO ; Yushi ZHANG
Author Information

1. 中国医学科学院北京协和医学院北京协和医院泌尿外科，北京　100730
Publication Type:Journal Article
Keywords: Adrenocortical carcinoma; Mitotane; Combination therapy
From: Chinese Journal of Urology 2025;46(7):547-548
CountryChina
Language:Chinese
Abstract: Adrenocortical carcinoma（ACC）is a rare and highly aggressive malignant tumor. Currently，mitotane is the first-line treatment. However，reports on neoadjuvant therapy for ACC using mitotane combined with immune checkpoint inhibitors remain scarce. This article reports a case of ACC. The patient was asymptomatic，and a right adrenal mass was detected during examination. Diagnostic imaging and endocrine evaluation confirmed the diagnosis of ACC. Due to the large tumor size，radical resection was initially considered unfeasible. After 7 months of mitotane therapy and two courses of tislelizumab，significant tumor shrinkage was achieved，allowing for successful open resection of the large right adrenal tumor combined with right nephrectomy. Postoperative histopathological examination confirmed the diagnosis of ACC. During the 3-month postoperative follow-up，no evidence of recurrence or metastasis was observed.